Our Reports
Automotive ReportsElectronics & SemiconductorTelecom & ITTechnology & ITConsumer GoodsHealthcareFood & BeveragesChemical
Our Links
About UsContact UsPress ReleaseNewsOur Blogs

Int'l : +1(646) 600-5072 | query@kbvresearch.com

Global Vaccine Adjuvants Market Size, Share & Industry Trends Analysis Report By Type (Particulate, Adjuvant Emulsion, Pathogen, Combination, and Others), By Administration, By Application, By Regional Outlook and Forecast, 2023 - 2030

Published Date : 20-Dec-2023

Pages: 265

Formats: PDF

The Global Vaccine Adjuvants Market size is expected to reach $2.1 billion by 2030, rising at a market growth of 3.7% CAGR during the forecast period.

Infectious diseases impose a substantial financial and health burden on the international community. Vaccine adjuvants play a pivotal role in enhancing the efficacy of vaccines against infectious diseases by amplifying and directing the immune response. Consequently, the infectious diseases segment would acquire nearly 65% of the total market share by 2030. The factors that aid in the increasing prevalence of infectious diseases are rapid urbanization, unplanned human habitats in densely populated urban pockets inhabited by the poor, inadequate healthcare infrastructure, and insufficient vaccination. Several contagious diseases, including malaria, dengue fever, chikungunya, influenza, measles, tuberculosis, and coronaviruses, including SARS, MERS, and COVID-19, are rapidly disseminated between cities via international commerce and travel. Thus, rising frequencies of infectious diseases have a positive effect on the market.

Vaccine Adjuvants Market Size - Global Opportunities and Trends Analysis Report 2019-2030

The major strategies followed by the market participants are Partnerships as the key developmental strategy to keep pace with the changing demands of end users. For instance, in October, 2023, SPI Pharma, Inc. signed a distribution partnership with Q-Vant Biosciences, Inc. The partnership involves the development of Q-Vant's Q-SAP saponin adjuvant technology. The partnership would provide saponin adjuvants to vaccine developers and manufacturers globally. Moreover, in May, 2023, Croda International PLC partnered with Botanical Solution Inc, to accelerate the production of pharmaceutical-grade vaccine adjuvant QS-21. The partnership would lead to the creation of a sustainable QS-21 supply chain.

KBV Cardinal Matrix - Market Competition Analysis

Based on the Analysis presented in the KBV Cardinal matrix; GlaxoSmithKline PLC and Merck & Co., Inc. are the forerunners in the Market. In April, 2020, GlaxoSmithKline PLC partnered with Sanofi. Under the partnership, the two companies would combine their respective offerings to develop an adjuvanted vaccine for COVID-19. Companies such as Seppic S.A., CSL Limited and SPI Pharma, Inc. are some of the key innovators in Market.

Vaccine Adjuvants Market - Competitive Landscape and Trends by Forecast 2030

COVID 19 Impact Analysis

The COVID-19 pandemic crisis had a predominantly positive effect on market expansion. The urgency to develop COVID-19 vaccines prompted advancements in adjuvant technologies. Researchers explored various adjuvant formulations to potentiate immune responses against the virus, leading to innovations and discoveries that had broader implications for future vaccines. As a consequence of the profitability and progress of innovative adjuvants, there was a surge in demand during the COVID-19 pandemic, and this upward trend is expected to persist for the foreseeable future.

Market Growth Factors

Rising proportion of aging population and chronic diseases

As the demographic landscape shifts toward an older population globally, there's a corresponding increase in susceptibility to infectious diseases and a reduced immune response to conventional vaccines among the elderly. This demographic shift has necessitated the development of more effective vaccines, where adjuvants play a pivotal role. The confluence of a growing chronic disease burden and an aging population has resulted in an elevated need for vaccines that are not only more efficacious but also appropriate for populations at risk. Consequently, the positive impact of adjuvants in addressing the unique immunological challenges posed by an aging and chronically ill population has contributed significantly to the expansion and advancement of the market.

Development in healthcare biotechnology

Biotechnology in the health sector is increasingly emerging as a catalyst for economic progress in developing nations and a crucial instrument in enhancing the effectiveness and availability of healthcare services for impoverished populations. Investing in and supporting research and development in the ever-evolving biotechnology field is crucial. Potentially addressing an even more significant number of healthcare challenges, the subsequent generation of biotechnology products offers brighter prospects for individuals around the globe. Consequently, the exponential advancement in biotechnology is driving the expansion of the market.

Market Restraining Factors

Side effects and high toxicity of adjuvants

Adjuvanted vaccines may cause more local and systemic adverse effects than non-adjuvanted vaccines (e.g., injection site redness, pain, swelling, fever, shivering, and body aches). However, adjuvants can also be toxic in and of themselves, with numerous adverse environmental and human health effects having been documented. Due to the need for more data, the impossibility of conducting controlled studies in humans to establish causation, and the potentially lengthy time between vaccination and onset of symptoms, such evaluations are exceedingly challenging. Thus, the side effects and toxicity of these adjuvants are restraining market growth.

Type Outlook

Based on type, the market is divided into pathogen, adjuvant emulsion, particulate, combination, and others. In 2022, the pathogen segment acquired a substantial revenue share in the market. The elicitation of protective immunity is facilitated by promoting appropriate immune system responses towards targeted pathogens at both the innate and adaptive stages through the careful and proper selection of adjuvants. Variable pathogens possess unique attributes that necessitate the host's ability to mount a corresponding immune response in opposition to them. Adjuvant selection aims to induce an immune response customized to pathogens by their distinct characteristics. Hence, the increasing rate of infectious diseases caused by pathogens drives the segment's growth.

Administration Outlook

Based on administration, the market is divided into oral, intradermal, intranasal, intramuscular, and others. The intranasal segment held a remarkable revenue share in the market in 2022. Lymphatic tissue, also known as nasal-associated lymphoid tissue (NALT), is abundant in the nasal cavity. It combines cellular and humoral immune responses to stimulate systemic and mucosal immunity. Intranasal vaccines offer a needle-free, non-invasive method of vaccine administration. This mode of delivery is particularly advantageous in terms of ease of administration, especially in populations where needle phobia might be a concern.

Vaccine Adjuvants Market Share and Industry Analysis Report 2022

Application Outlook

On the basis of application, the market is categorized into infectious diseases, cancer, and others. In 2022, the cancer segment witnessed a considerable revenue share in the market. Extensive research has been conducted on the potential for developing cancer adjuvants using animal and human models. Many of these vaccinations are therapeutic, stimulating the immune system to identify and eliminate well-established tumors through prophylactic vaccination against human papillomavirus-associated malignancies. Patients who have undergone surgical resection, chemotherapy, or radiotherapy, all of which induce an immune response, are the optimal candidates for cancer vaccines.

Vaccine Adjuvants Market Report Coverage
Report Attribute Details
Market size value in 2022 USD 1.5 Billion
Market size forecast in 2030 USD 2.1 Billion
Base Year 2022
Historical Period 2019 to 2021
Forecast Period 2023 to 2030
Revenue Growth Rate CAGR of 3.7% from 2023 to 2030
Number of Pages 265
Number of Table 394
Report coverage Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Competitive Landscape, Porter’s 5 Forces Analysis, Company Profiling, Companies Strategic Developments, SWOT Analysis, Winning Imperatives
Segments covered Type, Administration, Application, Region
Country scope
  • North America (US, Canada, Mexico, and Rest of North America)
  • Europe (Germany, UK, France, Russia, Spain, Italy, and Rest of Europe)
  • Asia Pacific (China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific)
  • LAMEA (Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA)
Companies Included GlaxoSmithKline PLC, Novavax, Inc., SPI Pharma, Inc. (Associated British Foods PLC), Agenus Inc., CSL Limited, InvivoGen SAS, Croda International PLC, Seppic S.A. (L’Air Liquide S.A.), Merck & Co., Inc. and Riboxx GmbH
Growth Drivers
  • Rising proportion of aging population and chronic diseases 
  • Development in healthcare biotechnology 
Restraints
  • Side effects and high toxicity of adjuvants 

Regional Outlook

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region witnessed the maximum revenue share in the market in 2022. The expansion of these adjuvants in North America is fueled by increased investments allocated to the research and development of novel therapeutics and a rise in the incidence of catastrophic epidemic diseases. As a result, immunization for both chronic and acute illnesses becomes necessary. Additionally, the geographic reach of significant market participants in the United States enhances product penetration.

Free Valuable Insights: Global Vaccine Adjuvants Market size to reach USD 2.1 Billion by 2030

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC, Novavax, Inc., SPI Pharma, Inc. (Associated British Foods PLC), Agenus Inc., CSL Limited, InvivoGen SAS, Croda International PLC, Seppic S.A. (L’Air Liquide S.A.), Merck & Co., Inc. and Riboxx GmbH

Strategies deployed in the Market

» Partnerships, Collaborations, and Agreements:

  • Oct-2023: SPI Pharma, Inc. signed a distribution partnership with Q-Vant Biosciences, Inc., an American pharmaceutical company. The partnership involves the development of Q-Vant's Q-SAP saponin adjuvant technology. The partnership would provide saponin adjuvants to vaccine developers and manufacturers globally.
  • May-2023: Croda International PLC partnered with Botanical Solution Inc, a plant-based API manufacturer, to accelerate the production of pharmaceutical-grade vaccine adjuvant QS-21. The partnership would lead to the creation of a sustainable QS-21 supply chain.
  • Feb-2023: Novavax, Inc. entered a partnership with the U.S. Department of Health and Human Services (HHS), to provide it with 1.5 million doses of the Novavax COVID-19 Vaccine. The partnership comes in line with Novavax's commitment to providing American people with a diverse COVID-19 vaccine portfolio.
  • Nov-2022: CSL Limited announced a licensing agreement with Arcturus Therapeutics Holdings Inc., an American biotechnology company. The partnership grants CSL access to Arcturus Therapeutics' self-amplifying mRNA vaccine platform and would allow them to develop next-generation influenza vaccines.
  • Mar-2022: Agenus Inc. entered a partnership with Targovax ASA, an immuno-oncology company. The partnership aimed to combine Agenus' QS-21 STIMULON adjuvant with Targovax’s TG mutant KRAS cancer vaccines to provide better treatment to patients suffering from KRAS-mutated cancer.
  • Aug-2021: SPI Pharma, Inc. signed a distribution partnership with Azelis Americas, a specialty chemicals company. The partnership expands SPI Pharma's footprint in the US and Canadian markets.
  • Aug-2020: Novavax, Inc. signed a partnership with Takeda Pharmaceutical Company Limited, a Japanese pharmaceutical company, to commercialize its NVX‑CoV2373 COVID‑19 vaccine candidate. The partnership expands the global availability of NVX‑
  • Aug-2020: Novavax, Inc. entered a partnership with Biologics, a biopharmaceutical Contract Development and Manufacturing Organization, to outsource the manufacturing operation of its coronavirus vaccine, NVX-CoV2373. The partnership would ensure the Vaccine supply for the US market.
  • Apr-2020: GlaxoSmithKline PLC partnered with Sanofi, a French pharmaceutical company. Under the partnership, the two companies would combine their respective offerings to develop an adjuvanted vaccine for COVID-19.
  • Feb-2020: GlaxoSmithKline PLC signed a partnership with Clover Biopharmaceuticals, a Chinese biotechnology company. Under the partnership, GlaxoSmithKline would provide Clover with its S-Trimer pandemic adjuvant system for evaluation in preclinical studies.

» Product Launches and Product Expansions:

  • Nov-2021: Seppic S.A. released MONTANIDE GEL P PR, an aqueous adjuvant. The adjuvant is based on polymeric technology and is meant specifically for avian injectable vaccine use.

» Acquisitions and Mergers:

  • Aug-2022: GlaxoSmithKline PLC took over Affinivax, Inc., a biopharmaceutical company. The acquisition strengthens GlaxoSmithKline's novel vaccine portfolio.
  • Aug-2020: Croda International PLC took over Avanti Polar Lipids, Inc., a drug delivery systems provider. The acquisition enhances Croda’s research and development (R&D) capability for drug delivery.

» Trials and Approvals:

  • May-2023: GlaxoSmithKline PLC received approval from the US Food and Drug Administration for its Arexvy, an RSV vaccine used for the treatment of lower respiratory tract disease (LRTD) in adults over 60 years old.

Scope of the Study

Market Segments Covered in the Report:

By Type

  • Particulate
  • Adjuvant Emulsion
  • Pathogen
  • Combination
  • Others

By Administration

  • Intramuscular
  • Intranasal
  • Oral
  • Intradermal
  • Others

By Application

  • Infectious Diseases
  • Cancer
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

  • GlaxoSmithKline PLC
  • Novavax, Inc.
  • SPI Pharma, Inc. (Associated British Foods PLC)
  • Agenus Inc.
  • CSL Limited
  • InvivoGen SAS
  • Croda International PLC
  • Seppic S.A. (L’Air Liquide S.A.)
  • Merck & Co., Inc.
  • Riboxx GmbH
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Vaccine Adjuvants Market, by Type
1.4.2 Global Vaccine Adjuvants Market, by Administration
1.4.3 Global Vaccine Adjuvants Market, by Application
1.4.4 Global Vaccine Adjuvants Market, by Geography
1.5 Methodology for the research

Chapter 2. Market at a Glance
2.1 Key Highlights

Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints

Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.2.4 Trials and Approvals
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
4.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements: 2020, Feb – 2023, Oct) Leading Players
4.4 Porter Five Forces Analysis

Chapter 5. Global Vaccine Adjuvants Market, by Type
5.1 Global Particulate Market, by Region
5.2 Global Adjuvant Emulsion Market, by Region
5.3 Global Pathogen Market, by Region
5.4 Global Combination Market, by Region
5.5 Global Others Market, by Region

Chapter 6. Global Vaccine Adjuvants Market, by Administration
6.1 Global Intramuscular Market, by Region
6.2 Global Intranasal Market, by Region
6.3 Global Oral Market, by Region
6.4 Global Intradermal Market, by Region
6.5 Global Others Market, by Region

Chapter 7. Global Vaccine Adjuvants Market, by Application
7.1 Global Infectious Diseases Market, by Region
7.2 Global Cancer Market, by Region
7.3 Global Others Market, by Region

Chapter 8. Global Vaccine Adjuvants Market, by Region
8.1 North America Vaccine Adjuvants Market
8.1.1 North America Vaccine Adjuvants Market, by Type
8.1.1.1 North America Particulate Market, by Country
8.1.1.2 North America Adjuvant Emulsion Market, by Country
8.1.1.3 North America Pathogen Market, by Country
8.1.1.4 North America Combination Market, by Country
8.1.1.5 North America Others Market, by Country
8.1.2 North America Vaccine Adjuvants Market, by Administration
8.1.2.1 North America Intramuscular Market, by Country
8.1.2.2 North America Intranasal Market, by Country
8.1.2.3 North America Oral Market, by Country
8.1.2.4 North America Intradermal Market, by Country
8.1.2.5 North America Others Market, by Country
8.1.3 North America Vaccine Adjuvants Market, by Application
8.1.3.1 North America Infectious Diseases Market, by Country
8.1.3.2 North America Cancer Market, by Country
8.1.3.3 North America Others Market, by Country
8.1.4 North America Vaccine Adjuvants Market, by Country
8.1.4.1 US Vaccine Adjuvants Market
8.1.4.1.1 US Vaccine Adjuvants Market, by Type
8.1.4.1.2 US Vaccine Adjuvants Market, by Administration
8.1.4.1.3 US Vaccine Adjuvants Market, by Application
8.1.4.2 Canada Vaccine Adjuvants Market
8.1.4.2.1 Canada Vaccine Adjuvants Market, by Type
8.1.4.2.2 Canada Vaccine Adjuvants Market, by Administration
8.1.4.2.3 Canada Vaccine Adjuvants Market, by Application
8.1.4.3 Mexico Vaccine Adjuvants Market
8.1.4.3.1 Mexico Vaccine Adjuvants Market, by Type
8.1.4.3.2 Mexico Vaccine Adjuvants Market, by Administration
8.1.4.3.3 Mexico Vaccine Adjuvants Market, by Application
8.1.4.4 Rest of North America Vaccine Adjuvants Market
8.1.4.4.1 Rest of North America Vaccine Adjuvants Market, by Type
8.1.4.4.2 Rest of North America Vaccine Adjuvants Market, by Administration
8.1.4.4.3 Rest of North America Vaccine Adjuvants Market, by Application
8.2 Europe Vaccine Adjuvants Market
8.2.1 Europe Vaccine Adjuvants Market, by Type
8.2.1.1 Europe Particulate Market, by Country
8.2.1.2 Europe Adjuvant Emulsion Market, by Country
8.2.1.3 Europe Pathogen Market, by Country
8.2.1.4 Europe Combination Market, by Country
8.2.1.5 Europe Others Market, by Country
8.2.2 Europe Vaccine Adjuvants Market, by Administration
8.2.2.1 Europe Intramuscular Market, by Country
8.2.2.2 Europe Intranasal Market, by Country
8.2.2.3 Europe Oral Market, by Country
8.2.2.4 Europe Intradermal Market, by Country
8.2.2.5 Europe Others Market, by Country
8.2.3 Europe Vaccine Adjuvants Market, by Application
8.2.3.1 Europe Infectious Diseases Market, by Country
8.2.3.2 Europe Cancer Market, by Country
8.2.3.3 Europe Others Market, by Country
8.2.4 Europe Vaccine Adjuvants Market, by Country
8.2.4.1 Germany Vaccine Adjuvants Market
8.2.4.1.1 Germany Vaccine Adjuvants Market, by Type
8.2.4.1.2 Germany Vaccine Adjuvants Market, by Administration
8.2.4.1.3 Germany Vaccine Adjuvants Market, by Application
8.2.4.2 UK Vaccine Adjuvants Market
8.2.4.2.1 UK Vaccine Adjuvants Market, by Type
8.2.4.2.2 UK Vaccine Adjuvants Market, by Administration
8.2.4.2.3 UK Vaccine Adjuvants Market, by Application
8.2.4.3 France Vaccine Adjuvants Market
8.2.4.3.1 France Vaccine Adjuvants Market, by Type
8.2.4.3.2 France Vaccine Adjuvants Market, by Administration
8.2.4.3.3 France Vaccine Adjuvants Market, by Application
8.2.4.4 Russia Vaccine Adjuvants Market
8.2.4.4.1 Russia Vaccine Adjuvants Market, by Type
8.2.4.4.2 Russia Vaccine Adjuvants Market, by Administration
8.2.4.4.3 Russia Vaccine Adjuvants Market, by Application
8.2.4.5 Spain Vaccine Adjuvants Market
8.2.4.5.1 Spain Vaccine Adjuvants Market, by Type
8.2.4.5.2 Spain Vaccine Adjuvants Market, by Administration
8.2.4.5.3 Spain Vaccine Adjuvants Market, by Application
8.2.4.6 Italy Vaccine Adjuvants Market
8.2.4.6.1 Italy Vaccine Adjuvants Market, by Type
8.2.4.6.2 Italy Vaccine Adjuvants Market, by Administration
8.2.4.6.3 Italy Vaccine Adjuvants Market, by Application
8.2.4.7 Rest of Europe Vaccine Adjuvants Market
8.2.4.7.1 Rest of Europe Vaccine Adjuvants Market, by Type
8.2.4.7.2 Rest of Europe Vaccine Adjuvants Market, by Administration
8.2.4.7.3 Rest of Europe Vaccine Adjuvants Market, by Application
8.3 Asia Pacific Vaccine Adjuvants Market
8.3.1 Asia Pacific Vaccine Adjuvants Market, by Type
8.3.1.1 Asia Pacific Particulate Market, by Country
8.3.1.2 Asia Pacific Adjuvant Emulsion Market, by Country
8.3.1.3 Asia Pacific Pathogen Market, by Country
8.3.1.4 Asia Pacific Combination Market, by Country
8.3.1.5 Asia Pacific Others Market, by Country
8.3.2 Asia Pacific Vaccine Adjuvants Market, by Administration
8.3.2.1 Asia Pacific Intramuscular Market, by Country
8.3.2.2 Asia Pacific Intranasal Market, by Country
8.3.2.3 Asia Pacific Oral Market, by Country
8.3.2.4 Asia Pacific Intradermal Market, by Country
8.3.2.5 Asia Pacific Others Market, by Country
8.3.3 Asia Pacific Vaccine Adjuvants Market, by Application
8.3.3.1 Asia Pacific Infectious Diseases Market, by Country
8.3.3.2 Asia Pacific Cancer Market, by Country
8.3.3.3 Asia Pacific Others Market, by Country
8.3.4 Asia Pacific Vaccine Adjuvants Market, by Country
8.3.4.1 China Vaccine Adjuvants Market
8.3.4.1.1 China Vaccine Adjuvants Market, by Type
8.3.4.1.2 China Vaccine Adjuvants Market, by Administration
8.3.4.1.3 China Vaccine Adjuvants Market, by Application
8.3.4.2 Japan Vaccine Adjuvants Market
8.3.4.2.1 Japan Vaccine Adjuvants Market, by Type
8.3.4.2.2 Japan Vaccine Adjuvants Market, by Administration
8.3.4.2.3 Japan Vaccine Adjuvants Market, by Application
8.3.4.3 India Vaccine Adjuvants Market
8.3.4.3.1 India Vaccine Adjuvants Market, by Type
8.3.4.3.2 India Vaccine Adjuvants Market, by Administration
8.3.4.3.3 India Vaccine Adjuvants Market, by Application
8.3.4.4 South Korea Vaccine Adjuvants Market
8.3.4.4.1 South Korea Vaccine Adjuvants Market, by Type
8.3.4.4.2 South Korea Vaccine Adjuvants Market, by Administration
8.3.4.4.3 South Korea Vaccine Adjuvants Market, by Application
8.3.4.5 Singapore Vaccine Adjuvants Market
8.3.4.5.1 Singapore Vaccine Adjuvants Market, by Type
8.3.4.5.2 Singapore Vaccine Adjuvants Market, by Administration
8.3.4.5.3 Singapore Vaccine Adjuvants Market, by Application
8.3.4.6 Malaysia Vaccine Adjuvants Market
8.3.4.6.1 Malaysia Vaccine Adjuvants Market, by Type
8.3.4.6.2 Malaysia Vaccine Adjuvants Market, by Administration
8.3.4.6.3 Malaysia Vaccine Adjuvants Market, by Application
8.3.4.7 Rest of Asia Pacific Vaccine Adjuvants Market
8.3.4.7.1 Rest of Asia Pacific Vaccine Adjuvants Market, by Type
8.3.4.7.2 Rest of Asia Pacific Vaccine Adjuvants Market, by Administration
8.3.4.7.3 Rest of Asia Pacific Vaccine Adjuvants Market, by Application
8.4 LAMEA Vaccine Adjuvants Market
8.4.1 LAMEA Vaccine Adjuvants Market, by Type
8.4.1.1 LAMEA Particulate Market, by Country
8.4.1.2 LAMEA Adjuvant Emulsion Market, by Country
8.4.1.3 LAMEA Pathogen Market, by Country
8.4.1.4 LAMEA Combination Market, by Country
8.4.1.5 LAMEA Others Market, by Country
8.4.2 LAMEA Vaccine Adjuvants Market, by Administration
8.4.2.1 LAMEA Intramuscular Market, by Country
8.4.2.2 LAMEA Intranasal Market, by Country
8.4.2.3 LAMEA Oral Market, by Country
8.4.2.4 LAMEA Intradermal Market, by Country
8.4.2.5 LAMEA Others Market, by Country
8.4.3 LAMEA Vaccine Adjuvants Market, by Application
8.4.3.1 LAMEA Infectious Diseases Market, by Country
8.4.3.2 LAMEA Cancer Market, by Country
8.4.3.3 LAMEA Others Market, by Country
8.4.4 LAMEA Vaccine Adjuvants Market, by Country
8.4.4.1 Brazil Vaccine Adjuvants Market
8.4.4.1.1 Brazil Vaccine Adjuvants Market, by Type
8.4.4.1.2 Brazil Vaccine Adjuvants Market, by Administration
8.4.4.1.3 Brazil Vaccine Adjuvants Market, by Application
8.4.4.2 Argentina Vaccine Adjuvants Market
8.4.4.2.1 Argentina Vaccine Adjuvants Market, by Type
8.4.4.2.2 Argentina Vaccine Adjuvants Market, by Administration
8.4.4.2.3 Argentina Vaccine Adjuvants Market, by Application
8.4.4.3 UAE Vaccine Adjuvants Market
8.4.4.3.1 UAE Vaccine Adjuvants Market, by Type
8.4.4.3.2 UAE Vaccine Adjuvants Market, by Administration
8.4.4.3.3 UAE Vaccine Adjuvants Market, by Application
8.4.4.4 Saudi Arabia Vaccine Adjuvants Market
8.4.4.4.1 Saudi Arabia Vaccine Adjuvants Market, by Type
8.4.4.4.2 Saudi Arabia Vaccine Adjuvants Market, by Administration
8.4.4.4.3 Saudi Arabia Vaccine Adjuvants Market, by Application
8.4.4.5 South Africa Vaccine Adjuvants Market
8.4.4.5.1 South Africa Vaccine Adjuvants Market, by Type
8.4.4.5.2 South Africa Vaccine Adjuvants Market, by Administration
8.4.4.5.3 South Africa Vaccine Adjuvants Market, by Application
8.4.4.6 Nigeria Vaccine Adjuvants Market
8.4.4.6.1 Nigeria Vaccine Adjuvants Market, by Type
8.4.4.6.2 Nigeria Vaccine Adjuvants Market, by Administration
8.4.4.6.3 Nigeria Vaccine Adjuvants Market, by Application
8.4.4.7 Rest of LAMEA Vaccine Adjuvants Market
8.4.4.7.1 Rest of LAMEA Vaccine Adjuvants Market, by Type
8.4.4.7.2 Rest of LAMEA Vaccine Adjuvants Market, by Administration
8.4.4.7.3 Rest of LAMEA Vaccine Adjuvants Market, by Application

Chapter 9. Company Profiles
9.1 Novavax, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expenses
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.1.6 SWOT Analysis
9.2 SPI Pharma, Inc. (Associated British Foods PLC)
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 Recent strategies and developments:
9.2.5.1 Partnerships, Collaborations, and Agreements:
9.3 Agenus Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Regional Analysis
9.3.4 Research & Development Expenses
9.3.5 Recent strategies and developments:
9.3.5.1 Partnerships, Collaborations, and Agreements:
9.3.6 SWOT Analysis
9.4 InvivoGen SAS
9.4.1 Company Overview
9.4.2 SWOT Analysis
9.5 Seppic S.A. (L’Air Liquide S.A.)
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expenses
9.5.5 Recent strategies and developments:
9.5.5.1 Product Launches and Product Expansions:
9.5.6 SWOT Analysis
9.6 Riboxx GmbH
9.6.1 Company Overview
9.7 GlaxoSmithKline PLC (GSK)
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Regional Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Partnerships, Collaborations, and Agreements:
9.7.5.2 Product Launches and Product Expansions:
9.7.5.3 Trials and Approvals:
9.7.6 SWOT Analysis
9.8 CSL Limited
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expenses
9.8.5 Recent strategies and developments:
9.8.5.1 Partnerships, Collaborations, and Agreements:
9.8.6 SWOT Analysis
9.9 Croda International PLC
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Segmental and Regional Analysis
9.9.4 Recent strategies and developments:
9.9.4.1 Partnerships, Collaborations, and Agreements:
9.9.4.2 Acquisition and Mergers:
9.10. Merck & Co., Inc.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expenses
9.10.5 Recent strategies and developments:
9.10.5.1 Acquisition and Mergers:
9.10.6 SWOT Analysis

Chapter 10. Winning Imperatives of Vaccine Adjuvants Market
TABLE 1 Global Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 2 Global Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Vaccine Adjuvants Market
TABLE 4 Product Launches And Product Expansions– Vaccine Adjuvants Market
TABLE 5 Acquisition and Mergers– Vaccine Adjuvants Market
TABLE 6 Trials and Approvals- Vaccine Adjuvants Market
TABLE 7 Global Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 8 Global Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 9 Global Particulate Market, by Region, 2019 - 2022, USD Million
TABLE 10 Global Particulate Market, by Region, 2023 - 2030, USD Million
TABLE 11 Global Adjuvant Emulsion Market, by Region, 2019 - 2022, USD Million
TABLE 12 Global Adjuvant Emulsion Market, by Region, 2023 - 2030, USD Million
TABLE 13 Global Pathogen Market, by Region, 2019 - 2022, USD Million
TABLE 14 Global Pathogen Market, by Region, 2023 - 2030, USD Million
TABLE 15 Global Combination Market, by Region, 2019 - 2022, USD Million
TABLE 16 Global Combination Market, by Region, 2023 - 2030, USD Million
TABLE 17 Global Others Market, by Region, 2019 - 2022, USD Million
TABLE 18 Global Others Market, by Region, 2023 - 2030, USD Million
TABLE 19 Global Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 20 Global Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 21 Global Intramuscular Market, by Region, 2019 - 2022, USD Million
TABLE 22 Global Intramuscular Market, by Region, 2023 - 2030, USD Million
TABLE 23 Global Intranasal Market, by Region, 2019 - 2022, USD Million
TABLE 24 Global Intranasal Market, by Region, 2023 - 2030, USD Million
TABLE 25 Global Oral Market, by Region, 2019 - 2022, USD Million
TABLE 26 Global Oral Market, by Region, 2023 - 2030, USD Million
TABLE 27 Global Intradermal Market, by Region, 2019 - 2022, USD Million
TABLE 28 Global Intradermal Market, by Region, 2023 - 2030, USD Million
TABLE 29 Global Others Market, by Region, 2019 - 2022, USD Million
TABLE 30 Global Others Market, by Region, 2023 - 2030, USD Million
TABLE 31 Global Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 32 Global Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 33 Global Infectious Diseases Market, by Region, 2019 - 2022, USD Million
TABLE 34 Global Infectious Diseases Market, by Region, 2023 - 2030, USD Million
TABLE 35 Global Cancer Market, by Region, 2019 - 2022, USD Million
TABLE 36 Global Cancer Market, by Region, 2023 - 2030, USD Million
TABLE 37 Global Others Market, by Region, 2019 - 2022, USD Million
TABLE 38 Global Others Market, by Region, 2023 - 2030, USD Million
TABLE 39 Global Vaccine Adjuvants Market, by Region, 2019 - 2022, USD Million
TABLE 40 Global Vaccine Adjuvants Market, by Region, 2023 - 2030, USD Million
TABLE 41 North America Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 42 North America Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 43 North America Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 44 North America Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 45 North America Particulate Market, by Country, 2019 - 2022, USD Million
TABLE 46 North America Particulate Market, by Country, 2023 - 2030, USD Million
TABLE 47 North America Adjuvant Emulsion Market, by Country, 2019 - 2022, USD Million
TABLE 48 North America Adjuvant Emulsion Market, by Country, 2023 - 2030, USD Million
TABLE 49 North America Pathogen Market, by Country, 2019 - 2022, USD Million
TABLE 50 North America Pathogen Market, by Country, 2023 - 2030, USD Million
TABLE 51 North America Combination Market, by Country, 2019 - 2022, USD Million
TABLE 52 North America Combination Market, by Country, 2023 - 2030, USD Million
TABLE 53 North America Others Market, by Country, 2019 - 2022, USD Million
TABLE 54 North America Others Market, by Country, 2023 - 2030, USD Million
TABLE 55 North America Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 56 North America Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 57 North America Intramuscular Market, by Country, 2019 - 2022, USD Million
TABLE 58 North America Intramuscular Market, by Country, 2023 - 2030, USD Million
TABLE 59 North America Intranasal Market, by Country, 2019 - 2022, USD Million
TABLE 60 North America Intranasal Market, by Country, 2023 - 2030, USD Million
TABLE 61 North America Oral Market, by Country, 2019 - 2022, USD Million
TABLE 62 North America Oral Market, by Country, 2023 - 2030, USD Million
TABLE 63 North America Intradermal Market, by Country, 2019 - 2022, USD Million
TABLE 64 North America Intradermal Market, by Country, 2023 - 2030, USD Million
TABLE 65 North America Others Market, by Country, 2019 - 2022, USD Million
TABLE 66 North America Others Market, by Country, 2023 - 2030, USD Million
TABLE 67 North America Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 68 North America Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 69 North America Infectious Diseases Market, by Country, 2019 - 2022, USD Million
TABLE 70 North America Infectious Diseases Market, by Country, 2023 - 2030, USD Million
TABLE 71 North America Cancer Market, by Country, 2019 - 2022, USD Million
TABLE 72 North America Cancer Market, by Country, 2023 - 2030, USD Million
TABLE 73 North America Others Market, by Country, 2019 - 2022, USD Million
TABLE 74 North America Others Market, by Country, 2023 - 2030, USD Million
TABLE 75 North America Vaccine Adjuvants Market, by Country, 2019 - 2022, USD Million
TABLE 76 North America Vaccine Adjuvants Market, by Country, 2023 - 2030, USD Million
TABLE 77 US Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 78 US Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 79 US Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 80 US Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 81 US Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 82 US Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 83 US Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 84 US Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 85 Canada Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 86 Canada Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 87 Canada Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 88 Canada Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 89 Canada Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 90 Canada Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 91 Canada Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 92 Canada Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 93 Mexico Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 94 Mexico Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 95 Mexico Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 96 Mexico Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 97 Mexico Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 98 Mexico Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 99 Mexico Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 100 Mexico Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 101 Rest of North America Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 102 Rest of North America Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 103 Rest of North America Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 104 Rest of North America Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 105 Rest of North America Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 106 Rest of North America Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 107 Rest of North America Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 108 Rest of North America Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 109 Europe Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 110 Europe Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 111 Europe Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 112 Europe Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 113 Europe Particulate Market, by Country, 2019 - 2022, USD Million
TABLE 114 Europe Particulate Market, by Country, 2023 - 2030, USD Million
TABLE 115 Europe Adjuvant Emulsion Market, by Country, 2019 - 2022, USD Million
TABLE 116 Europe Adjuvant Emulsion Market, by Country, 2023 - 2030, USD Million
TABLE 117 Europe Pathogen Market, by Country, 2019 - 2022, USD Million
TABLE 118 Europe Pathogen Market, by Country, 2023 - 2030, USD Million
TABLE 119 Europe Combination Market, by Country, 2019 - 2022, USD Million
TABLE 120 Europe Combination Market, by Country, 2023 - 2030, USD Million
TABLE 121 Europe Others Market, by Country, 2019 - 2022, USD Million
TABLE 122 Europe Others Market, by Country, 2023 - 2030, USD Million
TABLE 123 Europe Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 124 Europe Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 125 Europe Intramuscular Market, by Country, 2019 - 2022, USD Million
TABLE 126 Europe Intramuscular Market, by Country, 2023 - 2030, USD Million
TABLE 127 Europe Intranasal Market, by Country, 2019 - 2022, USD Million
TABLE 128 Europe Intranasal Market, by Country, 2023 - 2030, USD Million
TABLE 129 Europe Oral Market, by Country, 2019 - 2022, USD Million
TABLE 130 Europe Oral Market, by Country, 2023 - 2030, USD Million
TABLE 131 Europe Intradermal Market, by Country, 2019 - 2022, USD Million
TABLE 132 Europe Intradermal Market, by Country, 2023 - 2030, USD Million
TABLE 133 Europe Others Market, by Country, 2019 - 2022, USD Million
TABLE 134 Europe Others Market, by Country, 2023 - 2030, USD Million
TABLE 135 Europe Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 136 Europe Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 137 Europe Infectious Diseases Market, by Country, 2019 - 2022, USD Million
TABLE 138 Europe Infectious Diseases Market, by Country, 2023 - 2030, USD Million
TABLE 139 Europe Cancer Market, by Country, 2019 - 2022, USD Million
TABLE 140 Europe Cancer Market, by Country, 2023 - 2030, USD Million
TABLE 141 Europe Others Market, by Country, 2019 - 2022, USD Million
TABLE 142 Europe Others Market, by Country, 2023 - 2030, USD Million
TABLE 143 Europe Vaccine Adjuvants Market, by Country, 2019 - 2022, USD Million
TABLE 144 Europe Vaccine Adjuvants Market, by Country, 2023 - 2030, USD Million
TABLE 145 Germany Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 146 Germany Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 147 Germany Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 148 Germany Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 149 Germany Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 150 Germany Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 151 Germany Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 152 Germany Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 153 UK Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 154 UK Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 155 UK Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 156 UK Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 157 UK Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 158 UK Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 159 UK Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 160 UK Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 161 France Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 162 France Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 163 France Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 164 France Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 165 France Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 166 France Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 167 France Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 168 France Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 169 Russia Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 170 Russia Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 171 Russia Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 172 Russia Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 173 Russia Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 174 Russia Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 175 Russia Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 176 Russia Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 177 Spain Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 178 Spain Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 179 Spain Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 180 Spain Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 181 Spain Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 182 Spain Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 183 Spain Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 184 Spain Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 185 Italy Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 186 Italy Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 187 Italy Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 188 Italy Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 189 Italy Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 190 Italy Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 191 Italy Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 192 Italy Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 193 Rest of Europe Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 194 Rest of Europe Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 195 Rest of Europe Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 196 Rest of Europe Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 197 Rest of Europe Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 198 Rest of Europe Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 199 Rest of Europe Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 200 Rest of Europe Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 201 Asia Pacific Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 202 Asia Pacific Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 203 Asia Pacific Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 204 Asia Pacific Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 205 Asia Pacific Particulate Market, by Country, 2019 - 2022, USD Million
TABLE 206 Asia Pacific Particulate Market, by Country, 2023 - 2030, USD Million
TABLE 207 Asia Pacific Adjuvant Emulsion Market, by Country, 2019 - 2022, USD Million
TABLE 208 Asia Pacific Adjuvant Emulsion Market, by Country, 2023 - 2030, USD Million
TABLE 209 Asia Pacific Pathogen Market, by Country, 2019 - 2022, USD Million
TABLE 210 Asia Pacific Pathogen Market, by Country, 2023 - 2030, USD Million
TABLE 211 Asia Pacific Combination Market, by Country, 2019 - 2022, USD Million
TABLE 212 Asia Pacific Combination Market, by Country, 2023 - 2030, USD Million
TABLE 213 Asia Pacific Others Market, by Country, 2019 - 2022, USD Million
TABLE 214 Asia Pacific Others Market, by Country, 2023 - 2030, USD Million
TABLE 215 Asia Pacific Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 216 Asia Pacific Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 217 Asia Pacific Intramuscular Market, by Country, 2019 - 2022, USD Million
TABLE 218 Asia Pacific Intramuscular Market, by Country, 2023 - 2030, USD Million
TABLE 219 Asia Pacific Intranasal Market, by Country, 2019 - 2022, USD Million
TABLE 220 Asia Pacific Intranasal Market, by Country, 2023 - 2030, USD Million
TABLE 221 Asia Pacific Oral Market, by Country, 2019 - 2022, USD Million
TABLE 222 Asia Pacific Oral Market, by Country, 2023 - 2030, USD Million
TABLE 223 Asia Pacific Intradermal Market, by Country, 2019 - 2022, USD Million
TABLE 224 Asia Pacific Intradermal Market, by Country, 2023 - 2030, USD Million
TABLE 225 Asia Pacific Others Market, by Country, 2019 - 2022, USD Million
TABLE 226 Asia Pacific Others Market, by Country, 2023 - 2030, USD Million
TABLE 227 Asia Pacific Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 228 Asia Pacific Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 229 Asia Pacific Infectious Diseases Market, by Country, 2019 - 2022, USD Million
TABLE 230 Asia Pacific Infectious Diseases Market, by Country, 2023 - 2030, USD Million
TABLE 231 Asia Pacific Cancer Market, by Country, 2019 - 2022, USD Million
TABLE 232 Asia Pacific Cancer Market, by Country, 2023 - 2030, USD Million
TABLE 233 Asia Pacific Others Market, by Country, 2019 - 2022, USD Million
TABLE 234 Asia Pacific Others Market, by Country, 2023 - 2030, USD Million
TABLE 235 Asia Pacific Vaccine Adjuvants Market, by Country, 2019 - 2022, USD Million
TABLE 236 Asia Pacific Vaccine Adjuvants Market, by Country, 2023 - 2030, USD Million
TABLE 237 China Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 238 China Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 239 China Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 240 China Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 241 China Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 242 China Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 243 China Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 244 China Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 245 Japan Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 246 Japan Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 247 Japan Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 248 Japan Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 249 Japan Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 250 Japan Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 251 Japan Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 252 Japan Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 253 India Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 254 India Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 255 India Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 256 India Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 257 India Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 258 India Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 259 India Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 260 India Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 261 South Korea Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 262 South Korea Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 263 South Korea Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 264 South Korea Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 265 South Korea Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 266 South Korea Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 267 South Korea Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 268 South Korea Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 269 Singapore Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 270 Singapore Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 271 Singapore Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 272 Singapore Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 273 Singapore Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 274 Singapore Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 275 Singapore Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 276 Singapore Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 277 Malaysia Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 278 Malaysia Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 279 Malaysia Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 280 Malaysia Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 281 Malaysia Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 282 Malaysia Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 283 Malaysia Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 284 Malaysia Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 285 Rest of Asia Pacific Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 286 Rest of Asia Pacific Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 287 Rest of Asia Pacific Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 288 Rest of Asia Pacific Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 289 Rest of Asia Pacific Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 290 Rest of Asia Pacific Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 291 Rest of Asia Pacific Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 292 Rest of Asia Pacific Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 293 LAMEA Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 294 LAMEA Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 295 LAMEA Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 296 LAMEA Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 297 LAMEA Particulate Market, by Country, 2019 - 2022, USD Million
TABLE 298 LAMEA Particulate Market, by Country, 2023 - 2030, USD Million
TABLE 299 LAMEA Adjuvant Emulsion Market, by Country, 2019 - 2022, USD Million
TABLE 300 LAMEA Adjuvant Emulsion Market, by Country, 2023 - 2030, USD Million
TABLE 301 LAMEA Pathogen Market, by Country, 2019 - 2022, USD Million
TABLE 302 LAMEA Pathogen Market, by Country, 2023 - 2030, USD Million
TABLE 303 LAMEA Combination Market, by Country, 2019 - 2022, USD Million
TABLE 304 LAMEA Combination Market, by Country, 2023 - 2030, USD Million
TABLE 305 LAMEA Others Market, by Country, 2019 - 2022, USD Million
TABLE 306 LAMEA Others Market, by Country, 2023 - 2030, USD Million
TABLE 307 LAMEA Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 308 LAMEA Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 309 LAMEA Intramuscular Market, by Country, 2019 - 2022, USD Million
TABLE 310 LAMEA Intramuscular Market, by Country, 2023 - 2030, USD Million
TABLE 311 LAMEA Intranasal Market, by Country, 2019 - 2022, USD Million
TABLE 312 LAMEA Intranasal Market, by Country, 2023 - 2030, USD Million
TABLE 313 LAMEA Oral Market, by Country, 2019 - 2022, USD Million
TABLE 314 LAMEA Oral Market, by Country, 2023 - 2030, USD Million
TABLE 315 LAMEA Intradermal Market, by Country, 2019 - 2022, USD Million
TABLE 316 LAMEA Intradermal Market, by Country, 2023 - 2030, USD Million
TABLE 317 LAMEA Others Market, by Country, 2019 - 2022, USD Million
TABLE 318 LAMEA Others Market, by Country, 2023 - 2030, USD Million
TABLE 319 LAMEA Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 320 LAMEA Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 321 LAMEA Infectious Diseases Market, by Country, 2019 - 2022, USD Million
TABLE 322 LAMEA Infectious Diseases Market, by Country, 2023 - 2030, USD Million
TABLE 323 LAMEA Cancer Market, by Country, 2019 - 2022, USD Million
TABLE 324 LAMEA Cancer Market, by Country, 2023 - 2030, USD Million
TABLE 325 LAMEA Others Market, by Country, 2019 - 2022, USD Million
TABLE 326 LAMEA Others Market, by Country, 2023 - 2030, USD Million
TABLE 327 LAMEA Vaccine Adjuvants Market, by Country, 2019 - 2022, USD Million
TABLE 328 LAMEA Vaccine Adjuvants Market, by Country, 2023 - 2030, USD Million
TABLE 329 Brazil Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 330 Brazil Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 331 Brazil Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 332 Brazil Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 333 Brazil Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 334 Brazil Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 335 Brazil Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 336 Brazil Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 337 Argentina Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 338 Argentina Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 339 Argentina Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 340 Argentina Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 341 Argentina Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 342 Argentina Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 343 Argentina Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 344 Argentina Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 345 UAE Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 346 UAE Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 347 UAE Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 348 UAE Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 349 UAE Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 350 UAE Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 351 UAE Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 352 UAE Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 353 Saudi Arabia Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 354 Saudi Arabia Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 355 Saudi Arabia Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 356 Saudi Arabia Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 357 Saudi Arabia Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 358 Saudi Arabia Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 359 Saudi Arabia Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 360 Saudi Arabia Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 361 South Africa Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 362 South Africa Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 363 South Africa Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 364 South Africa Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 365 South Africa Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 366 South Africa Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 367 South Africa Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 368 South Africa Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 369 Nigeria Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 370 Nigeria Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 371 Nigeria Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 372 Nigeria Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 373 Nigeria Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 374 Nigeria Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 375 Nigeria Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 376 Nigeria Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 377 Rest of LAMEA Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 378 Rest of LAMEA Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 379 Rest of LAMEA Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 380 Rest of LAMEA Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 381 Rest of LAMEA Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 382 Rest of LAMEA Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 383 Rest of LAMEA Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 384 Rest of LAMEA Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 385 Key Information – Novavax, Inc.
TABLE 386 Key Information – SPI Pharma, Inc.
TABLE 387 Key Information – Agenus Inc.
TABLE 388 Key Information – InvivoGen SAS
TABLE 389 Key Information – Seppic S.A.
TABLE 390 Key Information – Riboxx GmbH
TABLE 391 Key Information – GlaxoSmithKline PLC
TABLE 392 Key Information – CSL Limited
TABLE 393 Key Information – Croda International PLC
TABLE 394 Key Information - Merck & Co., Inc.

List of Figures
FIG 1 Methodology for the research
FIG 2 Global Vaccine Adjuvants Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting the Vaccine Adjuvants Market
FIG 4 KBV Cardinal Matrix
FIG 5 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 6 Key Strategic Move: (Product Launches and Product Expansions : 2017, Jun – 2021, Jun) Leading Players
FIG 7 Porter’s Five Forces Analysis – Vaccine Adjuvants Market
FIG 8 Global Vaccine Adjuvants Market, share by Type, 2022
FIG 9 Global Vaccine Adjuvants Market, share by Type, 2030
FIG 10 Global Vaccine Adjuvants Market, by Type, 2019 - 2030, USD Million
FIG 11 Global Vaccine Adjuvants Market, share by Administration, 2022
FIG 12 Global Vaccine Adjuvants Market, share by Administration, 2030
FIG 13 Global Vaccine Adjuvants Market, by Administration, 2019 - 2030, USD Million
FIG 14 Global Vaccine Adjuvants Market, share by Application, 2022
FIG 15 Global Vaccine Adjuvants Market, share by Application, 2030
FIG 16 Global Vaccine Adjuvants Market, by Application, 2019 - 2030, USD Million
FIG 17 Global Vaccine Adjuvants Market, share by Region, 2022
FIG 18 Global Vaccine Adjuvants Market, share by Region, 2030
FIG 19 Global Vaccine Adjuvants Market, by Region, 2019 - 2030, USD Million
FIG 20 SWOT Analysis: Novavax, Inc.
FIG 21 SWOT Analysis: Agenus Inc.
FIG 22 SWOT Analysis: InvivoGen SAS
FIG 23 SWOT Analysis: Seppic S.A.
FIG 24 Recent strategies and developments: GlaxoSmithKline PLC
FIG 25 SWOT Analysis: GlaxoSmithKline PLC
FIG 26 SWOT Analysis: CSL Limited
FIG 27 SWOT Analysis: Merck & Co., Inc.

Purchase Full Report of
Vaccine Adjuvants Market

Buy Now

Avail up to 60% discount on subscription plans on

SUBSCRIPTION MODEL